Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699862 | 0.93 | MMP13 (0.36) | MMP13SLC22A8AGTR1AGTR2PTGER4 | |
| SCHEMBL6920079 | 0.89 | MMP13 (0.38) | MMP13SLC22A8HDAC6AGTR1AGTR2 | |
| SCHEMBL6289326 | 0.85 | MMP13 (0.43) | MMP13SLC22A8HDAC6AGTR1AGTR2 | |
| SCHEMBL6694967 | 0.81 | MMP13 (0.46) | MMP13SLC22A8HDAC6SLC6A3 | |
| SCHEMBL6696978 | 0.79 | PTGER4 (0.46) | MMP13HDAC6PTGER4 | |
| SCHEMBL6701922 | 0.78 | SCD (0.36) | MMP13SLC22A8AGTR1AGTR2PTGER4 | |
| SCHEMBL6289360 | 0.76 | MMP13 (0.46) | MMP13SLC22A8HDAC6HDAC1HDAC8 | |
| SCHEMBL6706890 | 0.73 | MMP13 (0.55) | MMP13SLC22A8HDAC6HDAC1HDAC8 | |
| SCHEMBL6292726 | 0.72 | MMP13 (0.46) | MMP13SLC22A8HDAC6HDAC1HDAC8 | |
| SCHEMBL5189013 | 0.69 | HDAC6 (0.50) | HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885SLC22A8 2959/4885HDAC6 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.